Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ALOX5AP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ALOX5AP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ALOX5AP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ALOX5AP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
GO:00321037 | Oral cavity | OSCC | positive regulation of response to external stimulus | 203/7305 | 427/18723 | 1.79e-04 | 1.22e-03 | 203 |
GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
GO:199074818 | Oral cavity | OSCC | cellular detoxification | 63/7305 | 116/18723 | 5.80e-04 | 3.31e-03 | 63 |
GO:009886918 | Oral cavity | OSCC | cellular oxidant detoxification | 55/7305 | 101/18723 | 1.16e-03 | 5.89e-03 | 55 |
GO:007124115 | Oral cavity | OSCC | cellular response to inorganic substance | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:009723718 | Oral cavity | OSCC | cellular response to toxic substance | 65/7305 | 124/18723 | 1.63e-03 | 7.74e-03 | 65 |
GO:009875418 | Oral cavity | OSCC | detoxification | 75/7305 | 152/18723 | 5.99e-03 | 2.28e-02 | 75 |
GO:007124816 | Oral cavity | OSCC | cellular response to metal ion | 93/7305 | 197/18723 | 1.14e-02 | 3.85e-02 | 93 |
GO:00313495 | Oral cavity | OSCC | positive regulation of defense response | 127/7305 | 278/18723 | 1.32e-02 | 4.39e-02 | 127 |
GO:003210314 | Oral cavity | EOLP | positive regulation of response to external stimulus | 84/2218 | 427/18723 | 1.72e-06 | 3.99e-05 | 84 |
GO:001003826 | Oral cavity | EOLP | response to metal ion | 71/2218 | 373/18723 | 3.32e-05 | 4.65e-04 | 71 |
GO:00515929 | Oral cavity | EOLP | response to calcium ion | 33/2218 | 149/18723 | 2.62e-04 | 2.54e-03 | 33 |
GO:003134912 | Oral cavity | EOLP | positive regulation of defense response | 53/2218 | 278/18723 | 3.00e-04 | 2.81e-03 | 53 |
GO:009886925 | Oral cavity | EOLP | cellular oxidant detoxification | 24/2218 | 101/18723 | 5.97e-04 | 5.02e-03 | 24 |
GO:00507274 | Oral cavity | EOLP | regulation of inflammatory response | 66/2218 | 386/18723 | 1.34e-03 | 9.33e-03 | 66 |
GO:000963625 | Oral cavity | EOLP | response to toxic substance | 48/2218 | 262/18723 | 1.37e-03 | 9.49e-03 | 48 |
GO:007124116 | Oral cavity | EOLP | cellular response to inorganic substance | 42/2218 | 226/18723 | 2.00e-03 | 1.28e-02 | 42 |
GO:199074825 | Oral cavity | EOLP | cellular detoxification | 24/2218 | 116/18723 | 4.36e-03 | 2.38e-02 | 24 |
GO:00464565 | Oral cavity | EOLP | icosanoid biosynthetic process | 14/2218 | 56/18723 | 4.81e-03 | 2.57e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALOX5AP | SNV | Missense_Mutation | novel | c.640N>G | p.Leu214Val | p.L214V | | protein_coding | deleterious_low_confidence(0) | benign(0.138) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ALOX5AP | insertion | Frame_Shift_Ins | novel | c.189_205dupAGGCAATGTTGTCCTGT | p.Leu69Ter | p.L69* | | protein_coding | | | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALOX5AP | SNV | Missense_Mutation | rs776630925 | c.246C>A | p.Phe82Leu | p.F82L | | protein_coding | deleterious(0.02) | benign(0.382) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
ALOX5AP | SNV | Missense_Mutation | rs770152662 | c.214N>A | p.Val72Ile | p.V72I | | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ALOX5AP | SNV | Missense_Mutation | rs768839702 | c.229G>A | p.Val77Met | p.V77M | | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALOX5AP | SNV | Missense_Mutation | | c.521N>A | p.Arg174His | p.R174H | | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD |
ALOX5AP | SNV | Missense_Mutation | novel | c.226A>T | p.Ser76Cys | p.S76C | | protein_coding | deleterious(0.01) | probably_damaging(0.922) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ALOX5AP | SNV | Missense_Mutation | novel | c.164N>G | p.Glu55Gly | p.E55G | | protein_coding | deleterious_low_confidence(0.04) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
ALOX5AP | SNV | Missense_Mutation | novel | c.459G>T | p.Lys153Asn | p.K153N | | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALOX5AP | SNV | Missense_Mutation | | c.251N>T | p.Ala84Val | p.A84V | | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |